#Macclean booster series#
The team estimated the hazard ratios of SARS-CoV-2 infections in individuals vaccinated with the primary series in comparison to those who had received their booster vaccine dose. Almost 96% of the samples sequenced during the follow-up period were infected with the SARS-CoV-2 Omicron variant. Participants who were aged 12 years and above and were eligible to receive a booster dose, that is, five months had passed since the participant had completed their mRNA primary vaccine series. The study included vaccinated participants from an ongoing longitudinal study called the prospective assessment of COVID-19 in a community (PACC) between 20 December 2021 and 24 February 2022.
The researchers of the present study estimated the relative vaccine effectiveness (VE) of COVID-19 messenger ribonucleic acid (mRNA) booster vaccines as compared to the primary two-dose vaccine series. COVID-19 vaccines have played a critical role in curbing COVID-19 transmission however, the waning efficacy of these vaccines has led to the administration of booster vaccines for better protection against infection and disease severity. To date, over 500 million confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases, including 6.2 million deaths, have been reported globally. Image Credit: Dmitry Demidovich/Shutterstock Background Study: Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation. In a recent study posted to the medRxiv* preprint server, researchers compared the effectiveness of the coronavirus disease 2019 (COVID-19) booster vaccine to that of the primary vaccine series. I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.By Bhavana Kunkalikar Reviewed by Aimee Molineux
#Macclean booster registration#
I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. This study was reviewed and approved by the Institutional Review Board at the Marshfield Clinic Research Institute. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. This work was supported by the US Centers for Disease Control and Prevention (Grant 75D30120C09259). The authors have declared no competing interest.
Our results support current booster recommendations. Relative VE was 66% (95% CI: 46%, 79%) favoring the booster dose compared to primary series vaccination. During a period of Omicron variant circulation, we estimated relative VE of COVID-19 mRNA booster vaccination versus primary two-dose series in an ongoing community cohort.
0 kommentar(er)
